Table 5.
Author | Type of study | Type of CL | Sample size (eyes) | Severity KC | BCLCVA (logMAR) (mean) | Follow-up (months) (mean) | Mean age or age (years) | Sex (female/male) |
---|---|---|---|---|---|---|---|---|
Ozkurt et al. [108] | Retrospective case series | SoftPerm CL | 24 | NR | Better than +0.5 | 23 | 25.78 | 8/6 |
Nau [107] | Retrospective | SynergEyes HCLs versus RPGCLs | 79 | NR | +0.2 | 3 | 36.17 | 32/21 |
Abdalla et al. [112] | Retrospective | SynergEyes HCLs | 61 | Moderate and severe | 0.0 To +0.1 (31.1%) +0.2 to +0.3 (62.3%) |
7.8 | 40 | 18/26 |
Carracedo et al. [113] | Prospective comparative | ClearKone HCLs versus patient habitual CL | 33 | Moderate and severe | −0.024 | 1 | 26.3 | 5/13 |
Hahemi et al. [106] | Comparative case series | ClearKone HCLs (group 1) versus RPGCLs (group 2) | 40 | Moderate | Group 1 : 0.01 Group 2 : 0.02 |
2 | Group 1: 33.71 Group 2: 32.16 |
21/19 |
BCLCVA: best contact lens corrected visual acuity; NR: not reported; OD: right eye; CL: contact lens. Mild KC (average sim K < 45 D). Moderate (average sim K 45–52 D). Severe (average sim K > 52 D).